CN108675989B - Fe3+ molecular fluorescence test agent and preparation method thereof - Google Patents
Fe3+ molecular fluorescence test agent and preparation method thereof Download PDFInfo
- Publication number
- CN108675989B CN108675989B CN201810380960.3A CN201810380960A CN108675989B CN 108675989 B CN108675989 B CN 108675989B CN 201810380960 A CN201810380960 A CN 201810380960A CN 108675989 B CN108675989 B CN 108675989B
- Authority
- CN
- China
- Prior art keywords
- compound
- tert
- butyl
- preparation
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000012360 testing method Methods 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 38
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 34
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract description 19
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 95
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 84
- 239000002904 solvent Substances 0.000 claims description 41
- 150000001875 compounds Chemical class 0.000 claims description 40
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 36
- 239000003054 catalyst Substances 0.000 claims description 35
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 33
- 229940126062 Compound A Drugs 0.000 claims description 29
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 29
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 28
- 239000000047 product Substances 0.000 claims description 26
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 24
- YCEJUWBZSJVVNE-UHFFFAOYSA-N tert-butyl 4-(aminomethyl)benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(CN)C=C1 YCEJUWBZSJVVNE-UHFFFAOYSA-N 0.000 claims description 24
- PBGZJUKYAHDTND-UHFFFAOYSA-N tert-butyl 4-cyanobenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(C#N)C=C1 PBGZJUKYAHDTND-UHFFFAOYSA-N 0.000 claims description 24
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical group OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 20
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 20
- ADCUEPOHPCPMCE-UHFFFAOYSA-N 4-cyanobenzoic acid Chemical compound OC(=O)C1=CC=C(C#N)C=C1 ADCUEPOHPCPMCE-UHFFFAOYSA-N 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 16
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 16
- 239000002244 precipitate Substances 0.000 claims description 16
- 238000005886 esterification reaction Methods 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- 230000032050 esterification Effects 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 10
- 239000011230 binding agent Substances 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 7
- 238000006482 condensation reaction Methods 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 6
- 239000012074 organic phase Substances 0.000 claims description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 6
- 239000010941 cobalt Substances 0.000 claims description 4
- 229910017052 cobalt Inorganic materials 0.000 claims description 4
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000008346 aqueous phase Substances 0.000 claims description 3
- 238000005984 hydrogenation reaction Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 claims description 3
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 230000006324 decarbonylation Effects 0.000 claims 2
- 238000006606 decarbonylation reaction Methods 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 abstract description 10
- 230000005284 excitation Effects 0.000 abstract description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract description 6
- 230000004044 response Effects 0.000 abstract description 5
- 230000027756 respiratory electron transport chain Effects 0.000 abstract description 4
- XJHABGPPCLHLLV-UHFFFAOYSA-N benzo[de]isoquinoline-1,3-dione Chemical compound C1=CC(C(=O)NC2=O)=C3C2=CC=CC3=C1 XJHABGPPCLHLLV-UHFFFAOYSA-N 0.000 abstract description 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 3
- 238000006862 quantum yield reaction Methods 0.000 abstract description 3
- 238000012546 transfer Methods 0.000 abstract description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 description 33
- 230000008569 process Effects 0.000 description 26
- 238000003786 synthesis reaction Methods 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 17
- 239000012085 test solution Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 11
- 230000008859 change Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 7
- 229940125904 compound 1 Drugs 0.000 description 7
- 229940125898 compound 5 Drugs 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 229940125782 compound 2 Drugs 0.000 description 6
- 229910021645 metal ion Inorganic materials 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002189 fluorescence spectrum Methods 0.000 description 3
- -1 iron ion Chemical class 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- UJEUBSWHCGDJQU-UHFFFAOYSA-N 4-chloro-1,8-naphthalic anhydride Chemical compound O=C1OC(=O)C2=CC=CC3=C2C1=CC=C3Cl UJEUBSWHCGDJQU-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 206010022979 Iron excess Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 241000220257 Matthiola Species 0.000 description 1
- 235000011378 Matthiola incana Nutrition 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical compound [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- RIVIDPPYRINTTH-UHFFFAOYSA-N n-ethylpropan-2-amine Chemical compound CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 238000001637 plasma atomic emission spectroscopy Methods 0.000 description 1
- 238000000918 plasma mass spectrometry Methods 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 235000021547 stock Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- LDDFOBAKMGVHTC-UHFFFAOYSA-N tert-butyl 2-(aminomethyl)benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1CN LDDFOBAKMGVHTC-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6432—Quenching
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Optics & Photonics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
本发明提供了Fe3+分子荧光测试剂及其制备方法。该Fe3+分子荧光测试剂具有式I所示结构。本发明提供的Fe3+分子荧光测试剂以1,8‑萘亚酰胺为荧光基团,使其具有良好的光稳定性,激发和发射光均为长波长可见光,斯托克斯位移大,量子产率高。同时,该Fe3+分子荧光测试剂中的基团对于Fe3+的灵敏度较高,其吡啶环中的氮和4‑位氨基氮能够与Fe3+发生络合形成离子络合体,从而能够引发电子转移或能量转移,使该测试剂在不同的Fe3+浓度下具有不同的荧光响应。以上原因也使得本发明提供的Fe3+分子荧光测试剂兼具了更好的测试准确性和灵敏度。
The present invention provides a Fe 3+ molecular fluorescence test agent and a preparation method thereof. The Fe 3+ molecular fluorescent test agent has the structure shown in formula I. The Fe 3+ molecular fluorescence test reagent provided by the present invention uses 1,8-naphthalimide as the fluorescent group, so that it has good photostability, the excitation and emission light are both long-wavelength visible light, and the Stokes shift is large. High quantum yield. At the same time, the Fe 3+ molecular fluorescence test agent in The sensitivity of the group to Fe 3+ is high, and the nitrogen in its pyridine ring and the amino nitrogen at the 4-position can be complexed with Fe 3+ to form an ion complex, which can induce electron transfer or energy transfer, so that the test agent Different fluorescence responses at different Fe 3+ concentrations. The above reasons also make the Fe 3+ molecular fluorescence test agent provided by the present invention have better test accuracy and sensitivity.
Description
技术领域technical field
本发明涉及有机合成与元素分析技术领域,具体而言,涉及一种Fe3+分子荧光测试剂及其制备方法。The invention relates to the technical field of organic synthesis and elemental analysis, in particular to a Fe 3+ molecular fluorescence test agent and a preparation method thereof.
背景技术Background technique
铁是体内最丰富的微量元素之一,它是构成血红蛋白、肌红蛋白及多种酶的重要成分,参与了氧摄取、氧代谢、电子转移等过程。如果体内缺少铁,可影响血红蛋白的合成,可使细胞色素c、核糖核苷酸还原酶、琥珀酸脱氢酶等酶的活性降低,从而导致严重的机体功能紊乱。人体内Fe3+含量的改变与许多疾病相关,如缺铁会导致贫血、癌症、糖尿病和器官功能障碍等,而铁过量则会通过芬顿反应产生活性氧诱发阿尔茨海默氏病、亨廷顿氏病和帕金森氏病等。因此,快速准确检测环境和人体内铁离子的含量对于环境安全和人类的健康具有十分重要的意义。Iron is one of the most abundant trace elements in the body. It is an important component of hemoglobin, myoglobin and various enzymes, and participates in processes such as oxygen uptake, oxygen metabolism, and electron transfer. If there is a lack of iron in the body, it can affect the synthesis of hemoglobin and reduce the activity of enzymes such as cytochrome c, ribonucleotide reductase, and succinate dehydrogenase, resulting in serious body dysfunction. The change of Fe 3+ content in the human body is related to many diseases, such as iron deficiency can lead to anemia, cancer, diabetes and organ dysfunction, etc., while iron excess can generate reactive oxygen species through the Fenton reaction to induce Alzheimer's disease, Huntington's disease, etc. disease and Parkinson's disease. Therefore, the rapid and accurate detection of iron ion content in the environment and human body is of great significance for environmental safety and human health.
目前,检测微量Fe3+的分析技术有很多种,包括原子吸收光谱法、等离子体发射光谱、等离子体质谱、电化学法、滴定法等。这些方法大多需要使用昂贵的大型仪器,操作复杂,便携性差且不适合在线实时监控。由于荧光分析法所需设备简单,并具有响应速度快、灵敏度高、操作简便等优点,因此利用荧光探针来定性与定量检测Fe3+已成为研究热点。At present, there are many analytical techniques for detecting trace Fe 3+ , including atomic absorption spectrometry, plasma emission spectrometry, plasma mass spectrometry, electrochemical method, titration method, etc. Most of these methods require the use of expensive large-scale instruments, are complicated to operate, have poor portability and are not suitable for online real-time monitoring. Due to the simple equipment required for fluorescence analysis, and the advantages of fast response, high sensitivity, and easy operation, the use of fluorescent probes for qualitative and quantitative detection of Fe 3+ has become a research hotspot.
近年来,关于Fe3+荧光探针的研究已有少量报道。其中大部分是以罗丹明为荧光基团的铁离子荧光探针,例如中国专利CN107011351A、CN 105884788A、Synthesis andevaluation of a novel rhodamine B-based'off-on'fluorescent chemosensor forthe selective determination of Fe3+ ions,Sensors and Actuators B:Chemicals,2017,242,921-931。罗丹明类荧光探针的检测原理为:通过与金属离子作用引起自身内酰胺螺环状结构发生开环,从而可以引起紫外可见吸收和荧光光谱变化,最终达到检测不同金属离子浓度的目的。In recent years, there have been few reports on the study of Fe 3+ fluorescent probes. Most of them are iron ion fluorescent probes with rhodamine as the fluorescent group, such as Chinese patents CN107011351A, CN 105884788A, Synthesis and evaluation of a novel rhodamine B-based'off-on'fluorescent chemosensor for the selective determination of Fe 3+ ions , Sensors and Actuators B: Chemicals, 2017, 242, 921-931. The detection principle of rhodamine-based fluorescent probes is as follows: by interacting with metal ions, the self-lactam spiro-ring structure is opened, which can cause changes in ultraviolet-visible absorption and fluorescence spectrum, and finally achieve the purpose of detecting different metal ion concentrations.
然而,由于罗丹明会参与离子耦合反应,因此其激发波长和发射波长会因检测离子的变化而变化,导致多种不同离子的罗丹明基荧光传感器不能用同一个激发和发射波长进行检测。而且上述报道的Fe3+荧光传感器激发波长约560nm,发射波长约580nm,其斯托克斯(Stockes) 位移只有20nm左右,普通光学分光镜片难以把激发光和荧光区分开来,从而影响检测结果,一般采用光谱分辨率高的光谱检测设备进行荧光信号采集,检测难度和成本会大大增加。However, because rhodamine participates in the ion coupling reaction, its excitation wavelength and emission wavelength will change due to the change of the detected ions, which leads to the fact that rhodamine-based fluorescence sensors with different ions cannot use the same excitation and emission wavelengths for detection. Moreover, the Fe 3+ fluorescence sensor reported above has an excitation wavelength of about 560 nm and an emission wavelength of about 580 nm, and its Stockes shift is only about 20 nm. It is difficult for ordinary optical spectroscopic lenses to distinguish the excitation light from the fluorescence, which affects the detection results. Generally, spectral detection equipment with high spectral resolution is used for fluorescence signal acquisition, which will greatly increase the difficulty and cost of detection.
基于以上原因,使用一种斯托克斯位移更大的荧光基团进行Fe3+分子荧光传感器设计是十分有必要的。For the above reasons, it is necessary to use a fluorophore with a larger Stokes shift for the design of Fe 3+ molecular fluorescence sensor.
发明内容SUMMARY OF THE INVENTION
本发明的主要目的在于提供一种Fe3+分子荧光测试剂及其制备方法,以解决现有技术中的 Fe3+分子荧光测试剂斯托克斯位移过小的问题。The main purpose of the present invention is to provide a Fe 3+ molecular fluorescent test agent and a preparation method thereof, so as to solve the problem of the Fe 3+ molecular fluorescent test agent being too small in Stokes shift in the prior art.
为了实现上述目的,根据本发明的一个方面,提供了一种Fe3+分子荧光测试剂,其具有式 I所示结构:In order to achieve the above object, according to one aspect of the present invention, a kind of Fe 3+ molecular fluorescence test agent is provided, which has the structure shown in formula I:
根据本发明的另一方面,还提供了一种Fe3+分子荧光测试剂的制备方法,其包括以下步骤:According to another aspect of the present invention, there is also provided a preparation method of Fe 3+ molecular fluorescence test agent, which comprises the following steps:
步骤S1,将化合物A和化合物B进行缩合反应,形成化合物C;化合物A、化合物B及化合物C的结构如下,其中化合物A中的X为卤素:In step S1, compound A and compound B are subjected to a condensation reaction to form compound C; the structures of compound A, compound B and compound C are as follows, wherein X in compound A is halogen:
步骤S2,将化合物C进行水解反应得到Fe3+分子荧光测试剂:In step S2, compound C is subjected to hydrolysis reaction to obtain Fe 3+ molecular fluorescence test agent:
进一步地,在步骤S1之前,制备方法还包括制备化合物A的步骤,其包括:将4-氰基苯甲酸与叔丁醇进行酯化反应,得到4-氰基苯甲酸叔丁酯;将4-氰基苯甲酸叔丁酯、催化剂及甲醇混合形成混合体系,向混合体系中通入氢气进行氢化反应,得到4-氨基甲基苯甲酸叔丁酯E;其中催化剂为镍催化剂、钯碳催化剂及钴催化剂中的一种或多种;将4-氨基甲基苯甲酸叔丁酯E与化合物F进行反应,得到化合物A;其中4-氨基甲基苯甲酸叔丁酯E、化合物F 具有如下结构:Further, before step S1, the preparation method further includes the step of preparing compound A, which includes: performing an esterification reaction with 4-cyanobenzoic acid and tert-butanol to obtain tert-butyl 4-cyanobenzoate; - tert-butyl cyanobenzoate, catalyst and methanol are mixed to form a mixed system, and hydrogen is introduced into the mixed system to carry out hydrogenation reaction to obtain tert-butyl 4-aminomethylbenzoate E; wherein the catalyst is a nickel catalyst, a palladium-carbon catalyst and one or more of the cobalt catalysts; 4-aminomethyl benzoic acid tert-butyl ester E and compound F are reacted to obtain compound A; wherein 4-amino methyl benzoic acid tert-butyl ester E, compound F have the following structure:
其中化合物F中的X为卤素。wherein X in compound F is halogen.
进一步地,步骤S1包括:将化合物A、化合物B及缚酸剂与第一溶剂混合,得到第一混合物;将第一混合物在80~100℃温度下进行缩合反应,得到第一产物体系;将第一产物体系冷却并倒入水中,过滤得到沉淀,即为化合物C;优选地,第一溶剂为N-甲基吡咯烷酮、N,N- 二甲基乙酰胺、二甲基亚砜、二甲基乙酰胺及四氢呋喃中的一种或多种;优选地,缚酸剂为 N,N-二异丙基乙胺、N,N-二甲基甲酰胺、4-二甲氨基吡啶及三乙胺中的一种或多种;优选地,化合物A、化合物B及缚酸剂之间的摩尔比为1~6:1~5:1~15。Further, step S1 includes: mixing compound A, compound B and acid binding agent with a first solvent to obtain a first mixture; subjecting the first mixture to a condensation reaction at a temperature of 80-100° C. to obtain a first product system; The first product system is cooled and poured into water, filtered to obtain a precipitate, which is compound C; preferably, the first solvent is N-methylpyrrolidone, N,N-dimethylacetamide, dimethyl sulfoxide, dimethyl sulfoxide One or more of acetamide and tetrahydrofuran; preferably, the acid binding agent is N,N-diisopropylethylamine, N,N-dimethylformamide, 4-dimethylaminopyridine and triethylamine One or more of amines; preferably, the molar ratio between compound A, compound B and acid binding agent is 1-6:1-5:1-15.
进一步地,在过滤步骤之后,步骤S1还包括对沉淀进行洗涤的步骤,洗涤步骤包括:将沉淀溶解在三氯甲烷中,向其中加入水进行洗涤,分液,得到有机相和水相;采用无水硫酸钠干燥有机相,过滤并蒸发,得到化合物C。Further, after the filtering step, step S1 further includes the step of washing the precipitate, and the washing step includes: dissolving the precipitate in chloroform, adding water to it for washing, and separating liquids to obtain an organic phase and an aqueous phase; The organic phase was dried over anhydrous sodium sulfate, filtered and evaporated to give compound C.
进一步地,步骤S2包括:将化合物C、羰基脱除试剂及第二溶剂混合并反应,得到第二产物体系;采用体积比为1:1的三氯甲烷/甲醇混合溶液稀释第二产物体系,然后蒸发溶剂,得到Fe3+分子荧光测试剂;优选地,羰基脱除试剂为三氟乙酸、体积比为1:2的盐酸和乙酸乙酯混合试剂、或硅胶;优选地,第二溶剂为二氯甲烷和/或氯仿;优选地,化合物C的摩尔数为羰基脱除试剂摩尔数的1.8~2.0%,优选为1.9%。Further, step S2 includes: mixing and reacting the compound C, the carbonyl removal reagent and the second solvent to obtain a second product system; using a chloroform/methanol mixed solution with a volume ratio of 1:1 to dilute the second product system, Then the solvent is evaporated to obtain Fe molecular fluorescence test reagent; preferably, the carbonyl removal reagent is trifluoroacetic acid, a mixed reagent of hydrochloric acid and ethyl acetate with a volume ratio of 1:2, or silica gel; preferably, the second solvent is Dichloromethane and/or chloroform; preferably, the mole number of compound C is 1.8-2.0% of the mole number of the carbonyl removal reagent, preferably 1.9%.
进一步地,将4-氰基苯甲酸与叔丁醇进行酯化反应的步骤包括:将4-氰基苯甲酸、酰化试剂第四溶剂混合并反应,得到中间物;除去中间物中的溶剂后,将其与酯化催化剂、叔丁醇混合并反应,得到第四产物体系;提纯第四产物体系,得到4-氰基苯甲酸叔丁酯;优选地,酰化试剂为草酰氯、氯化亚砜、三氯化磷及五氯化磷中的一种或多种;优选地,酯化催化剂为吡啶、N,N-二甲基甲酰胺、4-二甲氨基吡啶及三乙胺中的一种或多种;优选地,4-氰基苯甲酸和酰化试剂之间的摩尔比为2~3:3~5;酯化催化剂和叔丁醇之间的体积比为1~1.1:1。Further, the step of performing the esterification reaction between 4-cyanobenzoic acid and tert-butanol includes: mixing and reacting 4-cyanobenzoic acid and the fourth solvent of the acylating reagent to obtain an intermediate; removing the solvent in the intermediate Then, it is mixed and reacted with an esterification catalyst and tert-butanol to obtain a fourth product system; the fourth product system is purified to obtain tert-butyl 4-cyanobenzoate; preferably, the acylating reagents are oxalyl chloride, chlorine One or more of sulfoxide, phosphorus trichloride and phosphorus pentachloride; preferably, the esterification catalyst is pyridine, N,N-dimethylformamide, 4-dimethylaminopyridine and triethylamine one or more of; preferably, the molar ratio between the 4-cyanobenzoic acid and the acylating agent is 2~3:3~5; the volume ratio between the esterification catalyst and tert-butanol is 1~3 1.1:1.
进一步地,制备4-氨基甲基苯甲酸叔丁酯E的步骤中,4-氰基苯甲酸叔丁酯与催化剂之间的重量比为10~20:1~3;4-氰基苯甲酸叔丁酯与甲醇之间的重量比为1~3:8~20;优选地,通入氢气后,反应体系的压力为0.8~1.2MPa。Further, in the step of preparing tert-butyl 4-aminomethylbenzoate E, the weight ratio between tert-butyl 4-cyanobenzoate and the catalyst is 10-20:1-3; 4-cyanobenzoic acid The weight ratio between tert-butyl ester and methanol is 1-3:8-20; preferably, after hydrogen is introduced, the pressure of the reaction system is 0.8-1.2 MPa.
进一步地,将4-氨基甲基苯甲酸叔丁酯E与化合物F进行反应的步骤包括:将4-氨基甲基苯甲酸叔丁酯E、化合物F与第五溶剂混合并反应,得到第五产物体系;过滤第五产物体系,将得到的沉淀进行干燥,得到化合物A;优选地,第五溶剂为乙醇、甲醇、丙醇及异丙醇中的一种或多种;优选地,4-氨基甲基苯甲酸叔丁酯E与化合物F之间的摩尔比为1:1。Further, the step of reacting tert-butyl 4-aminomethylbenzoate E with compound F includes: mixing and reacting tert-butyl 4-aminomethylbenzoate E, compound F and the fifth solvent to obtain the fifth solvent. product system; filter the fifth product system, and dry the obtained precipitate to obtain compound A; preferably, the fifth solvent is one or more of ethanol, methanol, propanol and isopropanol; preferably, 4- The molar ratio between tert-butyl aminomethylbenzoate E and compound F was 1:1.
本发明提供的Fe3+分子荧光测试剂以1,8-萘亚酰胺为荧光基团,使其具有良好的光稳定性,激发(449nm)和发射光(533nm)均为长波长可见光,斯托克斯位移大(84nm),量子产率高。同时,该Fe3+分子荧光测试剂中的基团(测试基团)对于Fe3+的灵敏度较高,其吡啶环中的氮和4-位氨基氮能够与Fe3+发生络合形成离子络合体,从而能够引发电子转移或能量转移,使该测试剂在不同的Fe3+浓度下具有不同的荧光响应。以上原因也使得本发明提供的Fe3+分子荧光测试剂兼具了更好的测试准确性和灵敏度。The Fe 3+ molecular fluorescence test reagent provided by the present invention uses 1,8-naphthalimide as the fluorescent group, so that it has good photostability, and the excitation (449nm) and emission light (533nm) are both long-wavelength visible light. The Tox shift is large (84 nm) and the quantum yield is high. At the same time, the Fe 3+ molecular fluorescence test agent in The group (test group) has high sensitivity to Fe 3+ , and the nitrogen in the pyridine ring and the 4-amino nitrogen can be complexed with Fe 3+ to form an ionic complex, which can induce electron transfer or energy transfer , so that the test agent has different fluorescence responses at different Fe 3+ concentrations. The above reasons also make the Fe 3+ molecular fluorescence test agent provided by the present invention have better test accuracy and sensitivity.
附图说明Description of drawings
构成本申请的一部分的说明书附图用来提供对本发明的进一步理解,本发明的示意性实施例及其说明用于解释本发明,并不构成对本发明的不当限定。在附图中:The accompanying drawings forming a part of the present application are used to provide further understanding of the present invention, and the exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the attached image:
图1示出了本发明实施例1制备得到的叔丁基-4-胺甲基吡啶-1,8-萘二甲酰亚胺基甲基苯甲酸酯的核磁共振氢谱图;Fig. 1 shows the hydrogen nuclear magnetic resonance spectrum of tert-butyl-4-aminomethylpyridine-1,8-naphthalimide methylbenzoate prepared in Example 1 of the present invention;
图2示出了本发明实施例1制备得到的4-胺甲基吡啶-1,8-萘二甲酰亚氨基甲基苯甲酸的核磁共振氢谱图;Fig. 2 shows the hydrogen nuclear magnetic resonance spectrum of 4-aminomethylpyridine-1,8-naphthalimidomethylbenzoic acid prepared in Example 1 of the present invention;
图3示出了本发明实施例1中制得的Fe3+荧光测试液随着Fe3+待测液体积增加荧光光谱的变化图;Fig. 3 shows the change diagram of the fluorescence spectrum of the Fe 3+ fluorescent test solution prepared in Example 1 of the present invention as the volume of the Fe 3+ solution to be tested increases;
图4示出了本发明实施例1中制得的Fe3+荧光测试液随着Fe3+浓度增加荧光强度的变化图;Fig. 4 shows the variation diagram of the fluorescence intensity of Fe 3+ fluorescent test solution prepared in Example 1 of the present invention as the Fe 3+ concentration increases;
图5示出了本发明实施例1中制得的Fe3+荧光测试液对Fe3+的荧光选择性识别示意图;5 shows a schematic diagram of the selective identification of Fe 3+ fluorescence by the Fe 3+ fluorescent test solution prepared in Example 1 of the present invention;
图6示出了本发明实施例1制得的Fe3+荧光测试液检测Fe3+的抗干扰性识别示意图;6 shows a schematic diagram of the anti-interference identification of Fe 3+ detected by the Fe 3+ fluorescent test solution prepared in Example 1 of the present invention;
具体实施方式Detailed ways
需要说明的是,在不冲突的情况下,本申请中的实施例及实施例中的特征可以相互组合。下面将参考附图并结合实施例来详细说明本发明。It should be noted that the embodiments in the present application and the features of the embodiments may be combined with each other in the case of no conflict. The present invention will be described in detail below with reference to the accompanying drawings and in conjunction with the embodiments.
以下结合具体实施例对本申请作进一步详细描述,这些实施例不能理解为限制本申请所要求保护的范围。The present application will be described in further detail below with reference to specific embodiments, which should not be construed as limiting the scope of protection claimed by the present application.
正如背景技术部分所描述的,现有技术中的Fe3+分子荧光测试剂斯托克斯位移过小。As described in the background section, the Stokes shift of the Fe 3+ molecular fluorescent test agent in the prior art is too small.
为了解决上述问题,本发明提供了一种Fe3+分子荧光测试剂,其具有式I所示结构:In order to solve the above problems, the present invention provides a kind of Fe 3+ molecular fluorescence test agent, which has the structure shown in formula I:
本发明提供的Fe3+分子荧光测试剂以1,8-萘亚酰胺为荧光基团,使其具有良好的光稳定性,激发(449nm)和发射光(533nm)均为长波长可见光,斯托克斯位移大(84nm),量子产率高。同时,该Fe3+分子荧光测试剂中的基团(测试基团)对于Fe3+的灵敏度较高,其吡啶环中的氮和4-位氨基氮能够与Fe3+发生络合形成离子络合体,从而能够引发电子转移或能量转移,使该测试剂在不同的Fe3+浓度下具有不同的荧光响应。以上原因也使得本发明提供的Fe3+分子荧光测试剂兼具了更好的测试准确性和灵敏度。The Fe 3+ molecular fluorescence test reagent provided by the present invention uses 1,8-naphthalimide as the fluorescent group, so that it has good photostability, and the excitation (449nm) and emission light (533nm) are both long-wavelength visible light. The Tox shift is large (84 nm) and the quantum yield is high. At the same time, the Fe 3+ molecular fluorescence test agent in The group (test group) has high sensitivity to Fe 3+ , and the nitrogen in the pyridine ring and the 4-amino nitrogen can be complexed with Fe 3+ to form an ionic complex, which can induce electron transfer or energy transfer , so that the test agent has different fluorescence responses at different Fe 3+ concentrations. The above reasons also make the Fe 3+ molecular fluorescence test agent provided by the present invention have better test accuracy and sensitivity.
根据本发明的另一方面,还提供了一种Fe3+分子荧光测试剂的制备方法,其包括以下步骤:According to another aspect of the present invention, there is also provided a preparation method of Fe 3+ molecular fluorescence test agent, which comprises the following steps:
步骤S1,将化合物A和化合物B进行缩合反应,形成化合物C;化合物A、化合物B及化合物C的结构如下,其中化合物A中的X为卤素:In step S1, compound A and compound B are subjected to a condensation reaction to form compound C; the structures of compound A, compound B and compound C are as follows, wherein X in compound A is halogen:
步骤S2,将化合物C进行水解反应得到Fe3+分子荧光测试剂:In step S2, compound C is subjected to hydrolysis reaction to obtain Fe 3+ molecular fluorescence test agent:
如前文所述,本发明改制备方法制备的Fe3+分子荧光测试剂兼具了更好的测试准确性和灵敏度。且该制备方法中先以化合物A和化合物B进行缩合反应制备化合物C,再以化合物C 水解制备得到Fe3+分子荧光测试剂,该反应路线简单,成本较低,且工艺条件温和,适合工业化大规模生产。As mentioned above, the Fe 3+ molecular fluorescence test agent prepared by the modified preparation method of the present invention has both better test accuracy and sensitivity. In addition, in the preparation method, compound C is prepared by condensation reaction of compound A and compound B, and then the Fe 3+ molecular fluorescence test agent is prepared by hydrolysis of compound C. The reaction route is simple, the cost is low, and the process conditions are mild, which is suitable for industrialization. mass production.
上述化合物A可以选用市售产品,在一种优选的实施方式中,在步骤S1之前,该制备方法还包括制备化合物A的步骤,其包括:将4-氰基苯甲酸与叔丁醇进行酯化反应,得到4-氰基苯甲酸叔丁酯;将4-氰基苯甲酸叔丁酯、催化剂(镍催化剂、钯碳催化剂及钴催化剂中的一种或多种)及甲醇混合形成混合体系,向混合体系中通入氢气进行氢化反应,得到4-氨基甲基苯甲酸叔丁酯E;将4-氨基甲基苯甲酸叔丁酯E与化合物F进行反应,得到化合物A;其中4-氨基甲基苯甲酸叔丁酯E、化合物F具有如下结构:The above-mentioned compound A can be selected from commercially available products. In a preferred embodiment, before step S1, the preparation method further includes a step of preparing compound A, which includes: esterifying 4-cyanobenzoic acid with tert-butanol chemical reaction to obtain tert-butyl 4-cyanobenzoate; mix tert-butyl 4-cyanobenzoate, a catalyst (one or more of a nickel catalyst, a palladium-carbon catalyst and a cobalt catalyst) and methanol to form a mixed system , hydrogen is introduced into the mixed system to carry out hydrogenation reaction to obtain tert-butyl 4-aminomethylbenzoate E; tert-butyl 4-aminomethylbenzoate E is reacted with compound F to obtain compound A; wherein 4- Aminomethylbenzoic acid tert-butyl ester E, compound F have the following structures:
其中化合物F中的X为卤素。wherein X in compound F is halogen.
利用上述方法制备化合物A,路线简短、工艺简单、成本更低、产率相对较高。Using the above method to prepare compound A, the route is short, the process is simple, the cost is lower, and the yield is relatively high.
以上各合成步骤中的具体工艺条件可以进行调整,具体如下:The specific process conditions in each of the above synthesis steps can be adjusted, and the details are as follows:
在一种优选的实施方式中,上述步骤S1包括:将化合物A、化合物B及缚酸剂与第一溶剂混合,得到第一混合物;将第一混合物在80~100℃,更优选在90℃温度下进行缩合反应,得到第一产物体系;将第一产物体系冷却并倒入水中,过滤得到沉淀,即为化合物C。In a preferred embodiment, the above step S1 includes: mixing compound A, compound B and acid binding agent with a first solvent to obtain a first mixture; and heating the first mixture at 80-100°C, more preferably at 90°C The condensation reaction is carried out at the temperature to obtain the first product system; the first product system is cooled, poured into water, and filtered to obtain a precipitate, which is compound C.
优选地,第一溶剂包括但不限于N-甲基吡咯烷酮、N,N-二甲基乙酰胺、二甲基亚砜、二甲基乙酰胺及四氢呋喃中的一种或多种。Preferably, the first solvent includes, but is not limited to, one or more of N-methylpyrrolidone, N,N-dimethylacetamide, dimethylsulfoxide, dimethylacetamide and tetrahydrofuran.
优选地,上述缚酸剂为N-甲基吡咯烷酮、N,N-二甲基乙酰胺、二甲基亚砜、二甲基乙酰胺及四氢呋喃中的一种或多种。采用这几种缚酸剂,有利于进一步提高化合物A和化合物B 之间的反应效率,提高反应转化率。Preferably, the above acid binding agent is one or more of N-methylpyrrolidone, N,N-dimethylacetamide, dimethyl sulfoxide, dimethylacetamide and tetrahydrofuran. The use of these acid binding agents is beneficial to further improve the reaction efficiency between compound A and compound B, and to improve the reaction conversion rate.
优选地,化合物A、化合物B及缚酸剂之间的摩尔比为1~6:1~5:1~15;优选地,在过滤步骤之后,步骤S1还包括对沉淀进行洗涤的步骤,洗涤步骤包括:将沉淀溶解在三氯甲烷中,向其中加入水进行洗涤,分液,得到有机相和水相;采用无水硫酸钠干燥有机相,过滤并蒸发,得到化合物C。Preferably, the molar ratio between compound A, compound B and the acid binding agent is 1-6:1-5:1-15; preferably, after the filtering step, step S1 further includes the step of washing the precipitate, and the washing The steps include: dissolving the precipitate in chloroform, adding water for washing, and separating liquids to obtain an organic phase and an aqueous phase; drying the organic phase with anhydrous sodium sulfate, filtering and evaporating to obtain compound C.
举例如下:将叔丁基-4-氯-1,8-萘二甲酰亚胺基甲基苯甲酸酯(化合物A)、2-胺甲基吡啶 (化合物B)和N,N-二异丙基乙胺悬浮于N-甲基吡咯烷酮(NMP)并在90℃加热18小时。将混合物冷却并倒入水中。过滤得到沉淀,然后溶于CHCl3中并用水洗涤,分液。有机层用 Na2SO4干燥,过滤并蒸发,得到粗产物,将粗产物用55~60℃的热甲醇热打浆,过滤并用0~10℃的冷甲醇洗涤。所得固体(冷甲醇洗涤后的固体)用50~55℃的热CHCl3重结晶,得到黄色结晶叔丁基-4-胺甲基吡啶-1,8-萘二甲酰亚胺基甲基苯甲酸酯(化合物C)。Examples are as follows: tert-butyl-4-chloro-1,8-naphthalimidomethylbenzoate (compound A), 2-aminomethylpyridine (compound B) and N,N-dicarboxylate Isopropylethylamine was suspended in N-methylpyrrolidone (NMP) and heated at 90°C for 18 hours. Cool the mixture and pour into water. The precipitate was obtained by filtration, then dissolved in CHCl3 and washed with water, and the layers were separated. The organic layer was dried over Na2SO4 , filtered and evaporated to give the crude product, which was hot slurried with hot methanol at 55-60°C, filtered and washed with cold methanol at 0-10°C. The obtained solid (solid after washing with cold methanol) was recrystallized with hot CHCl3 at 50-55°C to obtain yellow crystals of tert-butyl-4-aminomethylpyridine-1,8-naphthalimidomethylbenzene Formate (Compound C).
在一种优选的实施方式中,上述步骤S2包括:将化合物C、羰基脱除试剂及第二溶剂混合并反应,得到第二产物体系;采用体积比为1:1的三氯甲烷/甲醇混合溶液稀释第二产物体系,然后蒸发溶剂,得到Fe3+分子荧光测试剂。采用羰基脱除试剂脱除反应物C的叔丁氧羰基(BOC)基团。采用体积比为1:1的三氯甲烷/甲醇混合溶液可以作为溶剂稀释产物,从而去除过量的羰基脱除试剂。In a preferred embodiment, the above step S2 includes: mixing and reacting compound C, the carbonyl removal reagent and the second solvent to obtain a second product system; using a chloroform/methanol mixture with a volume ratio of 1:1 The solution dilutes the second product system, and then evaporates the solvent to obtain the Fe 3+ molecular fluorescence test agent. The tert-butoxycarbonyl (BOC) group of reactant C was removed using a carbonyl removal reagent. The chloroform/methanol mixed solution with a volume ratio of 1:1 can be used as a solvent to dilute the product, thereby removing excess carbonyl removal reagent.
优选地,上述羰基脱除试剂为三氟乙酸、体积比为1:2的盐酸和乙酸乙酯混合试剂、或硅胶。出于减少副反应和简化后处理工艺的目的,更优选采用三氟乙酸作为羰基脱除试剂。优选地,第二溶剂为二氯甲烷和/或氯仿,其中采用二氯甲烷毒性更小、更环保。优选地,化合物C的的摩尔数为羰基脱除试剂摩尔数的的1.8~2.0%,更优选为1.9%。Preferably, the above-mentioned carbonyl removal reagent is trifluoroacetic acid, a mixed reagent of hydrochloric acid and ethyl acetate in a volume ratio of 1:2, or silica gel. For the purpose of reducing side reactions and simplifying the post-treatment process, trifluoroacetic acid is more preferably used as the carbonyl removal reagent. Preferably, the second solvent is dichloromethane and/or chloroform, wherein using dichloromethane is less toxic and more environmentally friendly. Preferably, the mole number of compound C is 1.8-2.0% of the mole number of the carbonyl removal reagent, more preferably 1.9%.
举例如下:将三氟乙酸(TFA)加入到叔丁基-4-胺甲基吡啶-1,8-萘二甲酰亚胺基甲基苯甲酸酯(化合物C)所在的CH2Cl2溶液中。将所得溶液在室温搅拌约1小时,直至薄层色谱检测(TLC)显示大部分叔丁基-4-胺甲基吡啶-1,8-萘二甲酰亚氨基甲基苯甲酸酯消失。然后将混合物用体积比1:1的CHCl3:MeOH稀释并将溶剂蒸发。重复4至8次以除去TFA,然后置于泵上30分钟使其完全干燥,得到黄色结晶4-胺甲基吡啶-1,8-萘二甲酰亚胺基甲基苯甲酸 (Fe3+分子荧光测试剂)。An example is as follows: trifluoroacetic acid (TFA) is added to CH2Cl2 where tert-butyl- 4 -aminomethylpyridine-1,8-naphthalimidomethylbenzoate (compound C) is located in solution. The resulting solution was stirred at room temperature for about 1 hour until thin layer chromatography (TLC) showed that most of the tert-butyl-4-aminomethylpyridine-1,8-naphthalimidomethylbenzoate disappeared. The mixture was then diluted with 1:1 by volume CHCI3 :MeOH and the solvent was evaporated. Repeat 4 to 8 times to remove TFA, then put it on the pump for 30 minutes to completely dry to give yellow crystals of 4-aminomethylpyridine-1,8-naphthalimidomethylbenzoic acid (Fe 3+ Molecular Fluorescence Test Agent).
在一种优选的实施方式中,将4-氰基苯甲酸与叔丁醇进行酯化反应的步骤包括:将4-氰基苯甲酸、酰化试剂和第四溶剂混合并反应,得到中间物;除去中间物中的溶剂后,将其与酯化催化剂、叔丁醇混合物混合并反应,得到第四产物体系;提纯第四产物体系,得到4-氰基苯甲酸叔丁酯。利用酰化试剂先与4-氰基苯甲酸进行酰化反应形成中间产物,然后在酯化催化剂的作用下能够与叔丁醇反应形成4-氰基苯甲酸叔丁酯。相较于酸与纯的直接反应,利用本发明提供的该路线制备4-氰基苯甲酸叔丁酯,原料转化率更高。优选地,酰化试剂为草酰氯、氯化亚砜、三氯化磷及五氯化磷中的一种或多种;优选地,酯化催化剂为吡啶、N,N- 二甲基甲酰胺(DMF)、4-二甲氨基吡啶(DMAP)及三乙胺中的一种或多种。In a preferred embodiment, the step of esterifying 4-cyanobenzoic acid with tert-butanol includes: mixing and reacting 4-cyanobenzoic acid, an acylating reagent and a fourth solvent to obtain an intermediate ; After removing the solvent in the intermediate, mix and react with the esterification catalyst and tert-butanol mixture to obtain the fourth product system; purify the fourth product system to obtain tert-butyl 4-cyanobenzoate. The acylation reagent is used for acylation reaction with 4-cyanobenzoic acid to form an intermediate product, and then it can react with tert-butanol under the action of an esterification catalyst to form tert-butyl 4-cyanobenzoate. Compared with the direct reaction between acid and pure, using the route provided by the present invention to prepare tert-butyl 4-cyanobenzoate, the raw material conversion rate is higher. Preferably, the acylating reagent is one or more of oxalyl chloride, thionyl chloride, phosphorus trichloride and phosphorus pentachloride; preferably, the esterification catalyst is pyridine, N,N-dimethylformamide One or more of (DMF), 4-dimethylaminopyridine (DMAP) and triethylamine.
优选地,4-氰基苯甲酸和酰化试剂之间的摩尔比为2~3:3~5,更优选2:3;将酯化催化剂和叔丁醇的总重量记为n,将除去溶剂的中间物的重量记为m,m:n为1~3:10~20,更优选为 3:20;酯化催化剂和叔丁醇之间的体积比为1~1.1:1,优选为1:1。Preferably, the molar ratio between 4-cyanobenzoic acid and the acylating agent is 2-3:3-5, more preferably 2:3; the total weight of the esterification catalyst and tert-butanol is denoted as n, and the removal of The weight of the solvent intermediate is denoted as m, and m:n is 1-3:10-20, more preferably 3:20; the volume ratio between the esterification catalyst and tert-butanol is 1-1.1:1, preferably 1:1.
举例如下:将4-氰基苯甲酸溶于无水CH2Cl2中,加入草酰氯和二甲基甲酰胺(DMF)。将所得混合物在室温下搅拌1小时,直至停止产生气体。除去溶剂,所得残余物用吡啶/叔丁醇混合物处理并在室温下搅拌6小时。减压蒸发溶剂,并将绿色残余物悬浮在水中,然后用乙酸乙酯萃取。将合并的有机层洗涤后用Na2SO4干燥并蒸发。粗产物经过乙酸乙酯/石油醚柱纯化后,得到白色固体4-氰基苯甲酸叔丁酯。An example is as follows: 4-cyanobenzoic acid is dissolved in dry CH2Cl2 , oxalyl chloride and dimethylformamide (DMF) are added. The resulting mixture was stirred at room temperature for 1 hour until gas evolution ceased. The solvent was removed and the resulting residue was treated with a pyridine/tert-butanol mixture and stirred at room temperature for 6 hours. The solvent was evaporated under reduced pressure, and the green residue was suspended in water, followed by extraction with ethyl acetate. The combined organic layers were washed, dried over Na2SO4 and evaporated. The crude product was purified by an ethyl acetate/petroleum ether column to give tert-butyl 4-cyanobenzoate as a white solid.
在一种优选的实施方式中,制备4-氨基甲基苯甲酸叔丁酯E的步骤中,4-氰基苯甲酸叔丁酯与催化剂之间的重量比为10~20:1~3,更优选为10:1;4-氰基苯甲酸叔丁酯与甲醇之间的重量比为1~3:8~20,更优选为3:20;优选地,通入氢气后,反应体系的压力为0.8~1.2MPa,更优选1MPa。利用上述工艺制备4-氨基甲基苯甲酸叔丁酯E,反应的效率更高,上述催化剂具体可以采用镍催化剂、钯碳催化剂及钴催化剂中的一种或多种。In a preferred embodiment, in the step of preparing tert-butyl 4-aminomethylbenzoate E, the weight ratio between tert-butyl 4-cyanobenzoate and the catalyst is 10-20:1-3, More preferably, it is 10:1; the weight ratio between tert-butyl 4-cyanobenzoate and methanol is 1~3:8~20, more preferably 3:20; The pressure is 0.8 to 1.2 MPa, more preferably 1 MPa. Utilizing the above-mentioned process to prepare tert-butyl 4-aminomethylbenzoate E, the reaction efficiency is higher, and the above-mentioned catalyst can specifically adopt one or more of a nickel catalyst, a palladium-carbon catalyst and a cobalt catalyst.
举例如下:将4-氰基苯甲酸叔丁酯和镍催化剂在甲醇中混合,于1MPa的压力下氢化16 小时。过滤除去催化剂,然后减压除去溶剂,得到白色固体4-氨基甲基苯甲酸叔丁酯。An example is as follows: tert-butyl 4-cyanobenzoate and nickel catalyst were mixed in methanol and hydrogenated at a pressure of 1 MPa for 16 hours. The catalyst was removed by filtration and then the solvent was removed under reduced pressure to yield tert-butyl 4-aminomethylbenzoate as a white solid.
在一种优选的实施方式中,将4-氨基甲基苯甲酸叔丁酯E与化合物F进行反应的步骤包括:将4-氨基甲基苯甲酸叔丁酯E、化合物F与第五溶剂混合并反应,得到第五产物体系;过滤第五产物体系,将得到的沉淀进行干燥,得到化合物A。In a preferred embodiment, the step of reacting tert-butyl 4-aminomethylbenzoate E with compound F comprises: mixing tert-butyl 4-aminomethylbenzoate E, compound F and a fifth solvent and react to obtain the fifth product system; filter the fifth product system, and dry the obtained precipitate to obtain compound A.
优选地,第五溶剂为乙醇、甲醇、丙醇及异丙醇中的一种或多种;优选地,4-氨基甲基苯甲酸叔丁酯E与化合物F之间的摩尔比为1:1。Preferably, the fifth solvent is one or more of ethanol, methanol, propanol and isopropanol; Preferably, the mol ratio between tert-butyl 4-aminomethylbenzoate E and compound F is 1: 1.
举例如下:将4-氯-1,8-萘二甲酸酐和4-氨基甲基苯甲酸叔丁酯放入乙醇中形成悬浮液。在室温下搅拌16小时。过滤得到的沉淀,在50℃干燥8小时,得到白色粉末叔丁基-4-氯-1,8- 萘二甲酰亚胺基甲基苯甲酸酯。An example is as follows: 4-chloro-1,8-naphthalenedicarboxylic anhydride and tert-butyl 4-aminomethylbenzoate are put into ethanol to form a suspension. Stir at room temperature for 16 hours. The obtained precipitate was filtered and dried at 50°C for 8 hours to obtain tert-butyl-4-chloro-1,8-naphthalimidomethylbenzoate as a white powder.
根据本发明的另一方面,还提供了一种Fe3+分子荧光测试液,其包括上述的Fe3+分子荧光测试剂和用于溶解Fe3+分子荧光测试剂的溶剂;优选溶剂为乙醇、乙腈、二甲基亚砜及N,N- 二甲基甲酰胺中的一种或多种,且Fe3+分子荧光测试液中Fe3+分子荧光测试剂的浓度为 1~10μmol/L。基于该Fe3+分子荧光测试剂优异的性能,使得上述Fe3+分子荧光测试液也兼具了良好的测试灵敏度和准确性。According to another aspect of the present invention, there is also provided a Fe 3+ molecular fluorescence test solution, which comprises the above-mentioned Fe 3+ molecular fluorescence test agent and a solvent for dissolving the Fe 3+ molecular fluorescence test agent; the preferred solvent is ethanol , one or more of acetonitrile, dimethyl sulfoxide and N,N-dimethylformamide, and the concentration of the Fe 3+ molecular fluorescence test agent in the Fe 3+ molecular fluorescence test solution is 1 to 10 μmol/L . Based on the excellent performance of the Fe 3+ molecular fluorescence test agent, the above-mentioned Fe 3+ molecular fluorescence test solution also has good test sensitivity and accuracy.
以下通过实施例进一步说明本发明的有益效果:The beneficial effects of the present invention are further described below by examples:
实施例1Example 1
化合物1的合成Synthesis of Compound 1
将4-氰基苯甲酸(80g,544mmol)溶于无水CH2Cl2(1000mL)中。加入草酰氯(104mL,816mmol)和二甲基甲酰胺(DMF)10mL。将所得的反应混合物在室温下搅拌1小时,直至停止产生气体。除去溶剂。所得残余物用600mL吡啶/叔丁醇混合物(1:1)处理并在室温下搅拌6小时。减压蒸发溶剂,并将绿色残余物悬浮在H2O中。含水悬浮液用乙酸乙酯(3×500mL) 萃取。将合并的有机层用10%KHSO4(2×500mL),H2O(500mL)NaHCO3(500mL),H2O (500mL)和盐水(500mL)洗涤。将溶剂用Na2SO4干燥并蒸发。粗产物通过使用乙酸乙酯/ 石油醚(1:4)的柱色谱法纯化,得到白色固体58g(产率52%)。4-Cyanobenzoic acid (80 g, 544 mmol) was dissolved in dry CH2Cl2 ( 1000 mL). Oxalyl chloride (104 mL, 816 mmol) and dimethylformamide (DMF) 10 mL were added. The resulting reaction mixture was stirred at room temperature for 1 hour until gas evolution ceased. Remove the solvent. The resulting residue was treated with 600 mL of a pyridine/tert-butanol mixture (1:1) and stirred at room temperature for 6 hours. The solvent was evaporated under reduced pressure and the green residue was suspended in H2O . The aqueous suspension was extracted with ethyl acetate (3 x 500 mL). The combined organic layers were washed with 10% KHSO4 (2 x 500 mL), H2O (500 mL), NaHCO3 (500 mL), H2O (500 mL) and brine (500 mL). The solvent was dried over Na2SO4 and evaporated. The crude product was purified by column chromatography using ethyl acetate/petroleum ether (1:4) to give a white solid 58g (52% yield).
化合物2的合成Synthesis of Compound 2
将4-氰基苯甲酸叔丁酯(58g,37mol)和镍催化剂(5.8g)在甲醇(500mL)中混合,于10kg的压力下氢化16小时。过滤除去催化剂,然后减压除去溶剂,得到白色固体47g(产率80%)。tert-Butyl 4-cyanobenzoate (58 g, 37 mol) and nickel catalyst (5.8 g) were mixed in methanol (500 mL) and hydrogenated under a pressure of 10 kg for 16 hours. The catalyst was removed by filtration, and then the solvent was removed under reduced pressure to obtain 47 g of a white solid (80% yield).
化合物3的合成Synthesis of Compound 3
将46.4g(200mmol)4-氯-1,8-萘二甲酸酐和41.4g(200mmol)4-氨基甲基苯甲酸叔丁酯放入250mLEtOH中形成悬浮液。在RT下搅拌16小时。过滤得到的沉淀,在50℃干燥8小时,得到白色粉末48g(产率57%)。46.4 g (200 mmol) of 4-chloro-1,8-naphthalenedicarboxylic anhydride and 41.4 g (200 mmol) of tert-butyl 4-aminomethylbenzoate were placed in 250 mL of EtOH to form a suspension. Stir at RT for 16 hours. The obtained precipitate was filtered and dried at 50°C for 8 hours to obtain 48 g of white powder (yield 57%).
化合物4的合成Synthesis of compound 4
将24.33g(225mmol)2-胺甲基吡啶和31.3g(74.3mmol)叔丁基-4-氯-1,8-萘二甲酰亚胺基甲基苯甲酸酯和13mL(74.6mmol)N,N-二异丙基乙胺悬浮于110mLN-甲基吡咯烷酮(NMP) 并在90℃加热18小时。将混合物冷却并倒入水(2L)中。过滤得到沉淀,然后溶于CHCl3 (800mL)中并用水(5×800mL)洗涤。有机层用Na2SO4干燥,过滤并蒸发,得到63.55g粗产物。将残余物用热甲醇(600mL)研磨,过滤并用冷甲醇(600mL)洗涤。所得固体用热 CHCl3重结晶,得到黄色结晶32.0g(产率87%),叔丁基-4-胺甲基吡啶-1,8-萘二甲酰亚胺基甲基苯甲酸酯,其核磁共振氢谱图如图1所示。Combine 24.33 g (225 mmol) 2-aminomethylpyridine and 31.3 g (74.3 mmol) tert-butyl-4-chloro-1,8-naphthalimidomethylbenzoate and 13 mL (74.6 mmol) N,N-Diisopropylethylamine was suspended in 110 mL of N-methylpyrrolidone (NMP) and heated at 90°C for 18 hours. The mixture was cooled and poured into water (2 L). The precipitate was obtained by filtration, then dissolved in CHCl3 (800 mL) and washed with water (5 x 800 mL). The organic layer was dried over Na2SO4 , filtered and evaporated to give 63.55 g of crude product. The residue was triturated with hot methanol (600 mL), filtered and washed with cold methanol (600 mL). The obtained solid was recrystallized with hot CHCl to obtain 32.0 g of yellow crystals (87% yield), tert-butyl-4-aminomethylpyridine-1,8-naphthalimidomethylbenzoate, Its H NMR spectrum is shown in Figure 1.
化合物5的合成Synthesis of compound 5
将87.5mL(1.14mol)三氟乙酸(TFA)加入到10.68g(21.64mmol)叔丁基-4-胺甲基吡啶-1,8-萘二甲酰亚胺基甲基苯甲酸酯在CH2Cl2(160mL)的溶液中。将所得溶液在室温搅拌约1小时,直至薄层色谱检测(TLC)显示大部分叔丁基-4-胺甲基吡啶-1,8-萘二甲酰亚氨基甲基苯甲酸酯消失。然后将混合物用1:1的CHCl3:MeOH(1.2L)稀释并将溶剂蒸发。重复6次以除去TFA,然后置于泵上30分钟使其完全干燥,得到黄色结晶9.35g(产率99%),4- 胺甲基吡啶-1,8-萘二甲酰亚氨基甲基苯甲酸,其核磁共振氢谱图如图2所示。87.5 mL (1.14 mol) of trifluoroacetic acid (TFA) was added to 10.68 g (21.64 mmol) of tert-butyl-4-aminomethylpyridine-1,8-naphthalimidomethylbenzoate in in CH2Cl2 ( 160 mL). The resulting solution was stirred at room temperature for about 1 hour until thin layer chromatography (TLC) showed that most of the tert-butyl-4-aminomethylpyridine-1,8-naphthalimidomethylbenzoate disappeared. The mixture was then diluted with 1:1 CHCl3 :MeOH (1.2 L) and the solvent was evaporated. This was repeated 6 times to remove TFA, then placed on the pump for 30 minutes to completely dry to obtain 9.35 g of yellow crystals (yield 99%), 4-aminomethylpyridine-1,8-naphthalimidomethyl Benzoic acid, its H NMR spectrum is shown in Figure 2.
Fe3+分子荧光测试液的制作Preparation of Fe 3+ Molecular Fluorescence Test Solution
称取4-胺甲基吡啶-1,8-萘二甲酰亚氨基甲基苯甲酸(化合物5)0.0022g于100ml溶液(体积比水:乙醇:乙腈=1:9:10)中得到5×10-2mol/L的Fe3+分子荧光测试储备液。Weigh 0.0022 g of 4-aminomethylpyridine-1,8-naphthalimidomethylbenzoic acid (compound 5) into 100 ml of solution (volume ratio water: ethanol: acetonitrile = 1:9:10) to obtain 5 ×10 -2 mol/L Fe 3+ molecular fluorescence test stock solution.
Fe3+分子荧光测试液的荧光性能测试Fluorescence performance test of Fe 3+ molecular fluorescence test solution
(1)Fe3+荧光测试液对不同浓度Fe3+的光谱特征(1) Spectral characteristics of Fe 3+ fluorescent test solution to different concentrations of Fe 3+
将0.1622g氯化铁溶于0.05mol/LpH 6.0的Tris-HCl缓冲液中,用100mL容量瓶定容制得 1.0×10-2mol/L的Fe3+待测溶液。吸取300μLFe3+荧光测试液加入到装有2700μl0.05mol/L Tris-HCl(pH6.0)缓冲液的荧光比色皿中,用枪头吸打均匀后即可得5μmol/L的Fe3+荧光测试液。在光电倍增管的电压为700V,激发波长和发射波长分别是449nm和533nm的条件下用荧光分光光度计测量其在上述一系列不同体积(0μl、30μl、60μl、90μl、120μl、150μl、180μl、210μl、 240μl、270μl和300μl)Fe3+待测液中的发射光荧光强度的变化。图3是本发明制得的Fe3+荧光测试液随着Fe3+待测液体积增加荧光光谱的变化图,可以看到Fe3+荧光试剂在Fe3+存在的情况下表现出强烈的荧光淬灭。随着Fe3+加入量的增加,该传感器在533nm处的荧光强度逐渐降低。图4是本发明制得的Fe3+荧光测试液随着Fe3+浓度增加荧光强度的变化图,从该图可以看到当Fe3+浓度在99μmol/L-909μmol/L的范围之内时,荧光强度与Fe3+浓度呈良好的线性关系,其拟合的线性方程可以对Fe3+进行定量检测。Dissolve 0.1622g of ferric chloride in 0.05mol/L Tris-HCl buffer at pH 6.0, and use a 100mL volumetric flask to make a 1.0×10 -2 mol/L Fe 3+ solution to be tested. Pipette 300μL of Fe 3+ fluorescent test solution and add it to the fluorescence cuvette containing 2700μl 0.05mol/L Tris-HCl (pH 6.0) buffer solution, pipette evenly with a pipette tip to get 5μmol/L Fe 3+ Fluorescent test solution. Under the condition that the voltage of the photomultiplier tube is 700V, and the excitation wavelength and emission wavelength are 449nm and 533nm, respectively, the fluorescence spectrophotometer is used to measure the above-mentioned series of different volumes (0μl, 30μl, 60μl, 90μl, 120μl, 150μl, 180μl, 210 μl, 240 μl, 270 μl and 300 μl) changes in the fluorescence intensity of emitted light in the Fe 3+ solution to be tested. Fig. 3 is a graph showing the change of the fluorescence spectrum of the Fe 3+ fluorescent test solution prepared by the present invention as the volume of the Fe 3+ solution to be tested increases, and it can be seen that the Fe 3+ fluorescent reagent exhibits a strong effect in the presence of Fe 3+ Fluorescence quenching. The fluorescence intensity of the sensor at 533 nm gradually decreased with the increase of Fe 3+ addition amount. Figure 4 is a graph showing the change of the fluorescence intensity of the Fe 3+ fluorescent test solution prepared by the present invention as the Fe 3+ concentration increases. From this figure, it can be seen that when the Fe 3+ concentration is within the range of 99 μmol/L-909 μmol/L When , the fluorescence intensity has a good linear relationship with the Fe 3+ concentration, and the fitted linear equation can quantitatively detect Fe 3+ .
(2)Fe3+荧光测试液对其他重金属离子的光谱特征(2) Spectral characteristics of Fe 3+ fluorescent test solution to other heavy metal ions
将16种金属离子盐[NaCl、KCl、CH3COOLi·2H2O、Al(NO3)3、CaCl2、MgCl2·6H2O、ZnCl2、 FeSO4·7H2O、CoCl2·6H2O、MnCl2·4H2O、CrCl3·6H2O、BaCl2·2H2O、NiCl2·6H2O、CuCl2·2H2O、CdCl2·2.5H2O、HgCl2]用0.05mol/L pH 6.0的Tris-HCl缓冲液精确配置成各自浓度为10mmol/L 的储备液。同时还配置各金属离子分别与Fe3+共存的标准液,使得每种标准液中单个金属离子与Fe3+的浓度均为10mmol/L。荧光选择性实验如图6所示,将浓度均为10mmol/L的Na+、 K+、Li+、Al3+、Ca2+、Mg2+、Zn2+、Fe2+、Co2+、Mn2+、Cr3+、Ba2+、Ni2+、Cu2+、Cd2+、Hg2+和Fe3+离子标准液分别取150μl加入装有5μmol/L Fe3+荧光试剂3ml的荧光比色皿中,在荧光稳定后,用波长为449nm的激发光检测其发射光荧光强度的变化(光电倍增管的电压为650V)。观察图5可知,Fe3+荧光测试液对Fe3+有明显的响应效果,并且在533nm处荧光强度降低到最低值,这说明该荧光试剂对Fe3+有很好的选择性。加入Cr3+后,传感器的荧光强度也略有降低,但其他等量金属离子对该试剂荧光发射强度基本没有影响。为了进一步研究其他常见的金属阳离子对Fe3+测定的干扰影响,我们进行了竞争实验,即将含有其他离子(浓度均为10mmol/L) 的10mmol/LFe3+溶液取150ul加入到含有5μmol/L Fe3+荧光试剂3ml的比色皿中进行测定(结果如图6白色柱状图所示)。通过竞争实验可知,除了Cr3+,其他离子和Fe3+共存时在533nm 下的荧光发射强度均没有显著变化。因此,除了Cr3+,其他常见金属阳离子和阴离子(不同金属阳离子是以氯化物、硝酸盐、硫酸盐或醋酸盐的形式加入)不会干扰的Fe3+的测定。而当 Cr3+的浓度降为50μmol/L时,对500μmol/L Fe3+的检测不再造成干扰。因此,此测试液用于实际应用是可行的。16 kinds of metal ion salts [NaCl, KCl, CH 3 COOLi·2H 2 O, Al(NO 3 ) 3 , CaCl 2 , MgCl 2 ·6H 2 O, ZnCl 2 , FeSO 4 ·7H 2 O, CoCl 2 ·6H For 2 O, MnCl 2 4H 2 O, CrCl 3 6H 2 O, BaCl 2 2H 2 O, NiCl 2 6H 2 O, CuCl 2 2H 2 O, CdCl 2 2.5H 2 O, HgCl 2 ] 0.05 mol/L Tris-HCl buffer pH 6.0 was precisely formulated into stock solutions with respective concentrations of 10 mmol/L. At the same time, standard solutions in which each metal ion and Fe 3+ coexist were also prepared, so that the concentration of a single metal ion and Fe 3+ in each standard solution was 10 mmol/L. The fluorescence selectivity experiment is shown in Figure 6. The concentrations of Na + , K + , Li + , Al 3+ , Ca 2+ , Mg 2+ , Zn 2+ , Fe 2+ , Co 2+ are all 10 mmol/L. , Mn 2+ , Cr 3+ , Ba 2+ , Ni 2+ , Cu 2+ , Cd 2+ , Hg 2+ and Fe 3+ ion standard solutions were respectively taken 150μl and added with 5μmol/L Fe 3+ fluorescent reagent 3ml In the fluorescence cuvette, after the fluorescence is stabilized, the change of the fluorescence intensity of the emitted light is detected by the excitation light with a wavelength of 449 nm (the voltage of the photomultiplier tube is 650V). Observing Figure 5, it can be seen that the Fe 3+ fluorescent test solution has an obvious response effect to Fe 3+ , and the fluorescence intensity decreases to the lowest value at 533 nm, which shows that the fluorescent reagent has good selectivity to Fe 3+ . After the addition of Cr 3+ , the fluorescence intensity of the sensor also decreased slightly, but other equivalent metal ions had no effect on the fluorescence emission intensity of the reagent. In order to further study the interference effect of other common metal cations on the determination of Fe 3+ , we carried out a competition experiment, that is, 150ul of 10mmol/LFe 3+ solution containing other ions (concentrations of 10mmol/L) was added to the solution containing 5μmol/L The measurement was carried out in a cuvette containing 3 ml of Fe 3+ fluorescent reagent (the results are shown in the white histogram in Figure 6). The competition experiment showed that except for Cr 3+ , the fluorescence emission intensity at 533 nm did not change significantly when other ions and Fe 3+ coexisted. Therefore, in addition to Cr 3+ , other common metal cations and anions (different metal cations are added as chloride, nitrate, sulfate or acetate) do not interfere with the determination of Fe 3+ . When the concentration of Cr 3+ was reduced to 50 μmol/L, the detection of Fe 3+ at 500 μmol/L no longer interfered. Therefore, it is feasible for this test fluid to be used in practical applications.
实施例2Example 2
该实施例中各步骤的工艺同实施例1,不同之处仅在于:化合物1的合成过程中,调整草酰氯的用量,使4-氰基苯甲酸和草酰氯的摩尔比为2:3,吡啶和叔丁醇之间的体积比为1.1:1。最终化合物1的产率为49%。The technique of each step in this embodiment is the same as that of Example 1, except that in the synthesis process of compound 1, the consumption of oxalyl chloride is adjusted so that the mol ratio of 4-cyanobenzoic acid and oxalyl chloride is 2:3, The volume ratio between pyridine and tert-butanol was 1.1:1. The yield of final compound 1 was 49%.
实施例3Example 3
该实施例中各步骤的工艺同实施例1,不同之处仅在于:化合物1的合成过程中,调整草酰氯的用量,使4-氰基苯甲酸和草酰氯的摩尔比为3:5。最终化合物1的产率为53%。The process of each step in this embodiment is the same as that of embodiment 1, except that: in the synthesis process of compound 1, the consumption of oxalyl chloride is adjusted so that the molar ratio of 4-cyanobenzoic acid and oxalyl chloride is 3:5. The yield of final compound 1 was 53%.
实施例4Example 4
该实施例中各步骤的工艺同实施例1,不同之处仅在于:化合物1的合成过程中,将草酰氯替换为氯化亚砜,且调整其用量使4-氰基苯甲酸和氯化亚砜的摩尔比为3:2,。将吡啶替换为 4-二甲氨基吡啶,并调整其用量使4-二甲氨基吡啶和叔丁醇之间的体积比为1.2:1,最终化合物1的产率为45%。The process of each step in this embodiment is the same as that of embodiment 1, except that: in the synthesis process of compound 1, oxalyl chloride is replaced with thionyl chloride, and its consumption is adjusted to make 4-cyanobenzoic acid and chlorinated The molar ratio of sulfoxide was 3:2. The pyridine was replaced with 4-dimethylaminopyridine, and its amount was adjusted so that the volume ratio between 4-dimethylaminopyridine and tert-butanol was 1.2:1, and the final yield of compound 1 was 45%.
实施例5Example 5
该实施例中各步骤的工艺同实施例1,不同之处仅在于:化合物2的合成过程中,调整催化剂的用量,使4-氰基苯甲酸叔丁酯与镍催化剂之间的重量比为20:3,调整甲醇的用量,使 4-氰基苯甲酸叔丁酯与甲醇之间的重量比为1:8。化合物2的产率为82%。The technique of each step in this embodiment is the same as that of Embodiment 1, except that in the synthesis process of compound 2, the consumption of the catalyst is adjusted so that the weight ratio between tert-butyl 4-cyanobenzoate and the nickel catalyst is 20:3, adjust the amount of methanol so that the weight ratio between tert-butyl 4-cyanobenzoate and methanol is 1:8. The yield of compound 2 was 82%.
实施例6Example 6
该实施例中各步骤的工艺同实施例1,不同之处仅在于:化合物2的合成过程中,调整催化剂的用量,使4-氰基苯甲酸叔丁酯与镍催化剂之间的重量比为20:3,调整甲醇的用量,使 4-氰基苯甲酸叔丁酯与甲醇之间的重量比为3:20。化合物2的产率为84%。The technique of each step in this embodiment is the same as that of Embodiment 1, except that in the synthesis process of compound 2, the consumption of the catalyst is adjusted so that the weight ratio between tert-butyl 4-cyanobenzoate and the nickel catalyst is 20:3, adjust the amount of methanol so that the weight ratio between tert-butyl 4-cyanobenzoate and methanol is 3:20. The yield of compound 2 was 84%.
实施例7Example 7
该实施例中各步骤的工艺同实施例1,不同之处仅在于:化合物2的合成过程中,将镍催化剂替换为钯碳催化剂,并调整催化剂的用量,使4-氰基苯甲酸叔丁酯与钯碳催化剂之间的重量比为15:1,调整甲醇的用量,使4-氰基苯甲酸叔丁酯与甲醇之间的重量比为1:6。化合物 2的产率为74%。The technique of each step in this embodiment is the same as that of Embodiment 1, except that in the synthesis process of compound 2, the nickel catalyst is replaced with a palladium-carbon catalyst, and the consumption of the catalyst is adjusted to make tert-butyl 4-cyanobenzoate. The weight ratio between the ester and the palladium-carbon catalyst was 15:1, and the amount of methanol was adjusted so that the weight ratio between tert-butyl 4-cyanobenzoate and methanol was 1:6. The yield of compound 2 was 74%.
实施例8Example 8
该实施例中各步骤的工艺同实施例1,不同之处仅在于:化合物4的合成过程中,调整 2-胺甲基吡啶和N,N-二异丙基乙胺的用量,使叔丁基-4-氯-1,8-萘二甲酰亚胺基甲基苯甲酸酯、 2-胺甲基吡啶和N,N-二异丙基乙胺之间的摩尔比为1:1:1。化合物4的产率为85%。The process of each step in this embodiment is the same as that of embodiment 1, except that: in the synthesis process of compound 4, the consumption of 2-aminomethylpyridine and N,N-diisopropylethylamine is adjusted so that tert-butyl 1:1 molar ratio between yl-4-chloro-1,8-naphthalimidomethylbenzoate, 2-aminomethylpyridine and N,N-diisopropylethylamine :1. The yield of compound 4 was 85%.
实施例9Example 9
该实施例中各步骤的工艺同实施例1,不同之处仅在于:化合物4的合成过程中,调整 2-胺甲基吡啶和N,N-二异丙基乙胺的用量,使叔丁基-4-氯-1,8-萘二甲酰亚胺基甲基苯甲酸酯、 2-胺甲基吡啶和N,N-二异丙基乙胺之间的摩尔比为6:5:15。化合物4的产率为82%。The process of each step in this embodiment is the same as that of embodiment 1, except that: in the synthesis process of compound 4, the consumption of 2-aminomethylpyridine and N,N-diisopropylethylamine is adjusted so that tert-butyl The molar ratio between yl-4-chloro-1,8-naphthalimidomethylbenzoate, 2-aminomethylpyridine and N,N-diisopropylethylamine is 6:5 :15. The yield of compound 4 was 82%.
实施例10Example 10
该实施例中各步骤的工艺同实施例1,不同之处仅在于:化合物4的合成过程中,将N, N-二异丙基乙胺替换为三乙胺,并调整2-胺甲基吡啶和三乙胺的用量,使叔丁基-4-氯-1,8-萘二甲酰亚胺基甲基苯甲酸酯、2-胺甲基吡啶和三乙胺之间的摩尔比为8:5:5。化合物4的产率为73%。The process of each step in this example is the same as that of Example 1, except that in the synthesis process of compound 4, N, N-diisopropylethylamine was replaced with triethylamine, and 2-aminomethyl was adjusted. The amount of pyridine and triethylamine used to make the molar ratio between tert-butyl-4-chloro-1,8-naphthalimidomethylbenzoate, 2-aminomethylpyridine and triethylamine 8:5:5. The yield of compound 4 was 73%.
实施例11Example 11
该实施例中各步骤的工艺同实施例1,不同之处仅在于:化合物5的合成过程中,调整三氟乙酸的用量,使叔丁基-4-胺甲基吡啶-1,8-萘二甲酰亚胺基甲基苯甲酸酯的摩尔数为三氟乙酸摩尔数的1.8%。化合物5的产率为97%。The process of each step in this example is the same as that of Example 1, except that: in the synthesis process of compound 5, the consumption of trifluoroacetic acid was adjusted so that tert-butyl-4-aminomethylpyridine-1,8-naphthalene was The moles of dicarboximidomethylbenzoate were 1.8% of the moles of trifluoroacetic acid. The yield of compound 5 was 97%.
实施例12Example 12
该实施例中各步骤的工艺同实施例1,不同之处仅在于:化合物5的合成过程中,调整三氟乙酸的用量,使叔丁基-4-胺甲基吡啶-1,8-萘二甲酰亚胺基甲基苯甲酸酯的摩尔数为三氟乙酸摩尔数的2.0%。化合物5的产率为98%。The process of each step in this example is the same as that of Example 1, except that: in the synthesis process of compound 5, the consumption of trifluoroacetic acid was adjusted so that tert-butyl-4-aminomethylpyridine-1,8-naphthalene was The moles of dicarboximidomethylbenzoate were 2.0% of the moles of trifluoroacetic acid. The yield of compound 5 was 98%.
实施例13Example 13
该实施例中各步骤的工艺同实施例1,不同之处仅在于:化合物5的合成过程中,将三氟乙酸替换为体积比为1:2的盐酸和乙酸乙酯混合试剂,并调整其用量,叔丁基-4-胺甲基吡啶 -1,8-萘二甲酰亚胺基甲基苯甲酸酯的摩尔数为该混合试剂摩尔数的3.0%。化合物5的产率为 75%。The process of each step in this embodiment is the same as that of embodiment 1, except that: in the synthesis process of compound 5, trifluoroacetic acid is replaced with a mixed reagent of hydrochloric acid and ethyl acetate with a volume ratio of 1:2, and the To be used, the mole number of tert-butyl-4-aminomethylpyridine-1,8-naphthalimidomethyl benzoate is 3.0% of the mole number of the mixed reagent. The yield of compound 5 was 75%.
由上述实施例可知,本发明提供的Fe3+分子荧光测试剂在测量样品中Fe3+浓度时具有测量效率高、灵敏度高、准确性好等优点。It can be seen from the above examples that the Fe 3+ molecular fluorescence test agent provided by the present invention has the advantages of high measurement efficiency, high sensitivity and good accuracy when measuring the Fe 3+ concentration in the sample.
以上所述仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。The above descriptions are only preferred embodiments of the present invention, and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and changes. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included within the protection scope of the present invention.
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810380960.3A CN108675989B (en) | 2018-04-25 | 2018-04-25 | Fe3+ molecular fluorescence test agent and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810380960.3A CN108675989B (en) | 2018-04-25 | 2018-04-25 | Fe3+ molecular fluorescence test agent and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108675989A CN108675989A (en) | 2018-10-19 |
CN108675989B true CN108675989B (en) | 2019-07-02 |
Family
ID=63802088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810380960.3A Active CN108675989B (en) | 2018-04-25 | 2018-04-25 | Fe3+ molecular fluorescence test agent and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108675989B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109593078B (en) * | 2018-12-29 | 2021-01-01 | 太原师范学院 | N-butyl-4-hydroxy-1, 8-naphthalimide-3-formaldehyde- (2-pyridine) hydrazone and application thereof |
CN116063193B (en) * | 2022-10-08 | 2025-02-07 | 中国林业科学研究院林产化学工业研究所 | Preparation method and application of castor oil-based multicolor fluorescent compound |
CN118388453B (en) * | 2024-04-19 | 2025-03-14 | 广东医科大学 | Fluorescent probe, preparation method and application thereof, and method for detecting iron ions |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634689A (en) * | 1985-10-31 | 1987-01-06 | Schering Corporation | Phosphinylalkanoyl imino acids |
US8097725B2 (en) * | 2004-12-03 | 2012-01-17 | Roche Diagnostics Operations, Inc. | Luminescent indicator dye and optical sensor |
US9360474B2 (en) * | 2012-11-29 | 2016-06-07 | Opti Medical Systems, Inc. | Multi-layer device for selectively determining magnesium ion |
CN103408440B (en) * | 2013-08-20 | 2014-12-10 | 天津希恩思生化科技有限公司 | Organic compound for detecting content of metal ions in water environment |
CN104292204B (en) * | 2014-09-05 | 2016-03-16 | 苏州福来兹检测科技有限公司 | A kind of compound for measuring metal ion content in water surrounding and application thereof |
CN104341347B (en) * | 2014-10-21 | 2018-02-23 | 苏州福来兹检测科技有限公司 | A kind of organic compound and its application for being used to prepare wide pH value fluorescence probe |
-
2018
- 2018-04-25 CN CN201810380960.3A patent/CN108675989B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN108675989A (en) | 2018-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Nickel (II) and iron (III) selective off-on-type fluorescence probes based on perylene tetracarboxylic diimide | |
Yang et al. | A highly selective “turn-on” fluorescent sensor for zinc ion based on a cinnamyl pyrazoline derivative and its imaging in live cells | |
Jiao et al. | A schiff-base dual emission ratiometric fluorescent chemosensor for Hg2+ ions and its application in cellular imaging | |
Wu et al. | A novel Cd II-based metal–organic framework as a multi-responsive luminescent sensor for Fe 3+, MnO 4−, Cr 2 O 7 2−, salicylaldehyde and ethylenediamine detection with high selectivity and sensitivity | |
CN108675989B (en) | Fe3+ molecular fluorescence test agent and preparation method thereof | |
CN108587605B (en) | Fe3+Molecular fluorescent compound and preparation method thereof | |
Liu et al. | A dual thiourea-appended perylenebisimide “turn-on” fluorescent chemosensor with high selectivity and sensitivity for Hg2+ in living cells | |
CN106220640A (en) | One class mercury ion fluorescence probe and its preparation method and application | |
CN108456514B (en) | Fluorescein-based fluorescent probe for detecting mercury ions, preparation method and application thereof | |
CN106831642A (en) | Fluorescent probe for detecting zinc ions or pyrophosphate, preparation method and application | |
Wu et al. | A stable lanthanum-based metal-organic framework as fluorescent sensor for detecting TNP and Fe3+ with hyper-sensitivity and ultra-selectivity | |
CN112209871A (en) | Zinc ion fluorescent probe based on tetraphenylethylene and preparation method and application thereof | |
CN109060733B (en) | Iron ion molecular fluorescence sensor and preparation method thereof | |
CN108864046B (en) | Fe2+Molecular fluorescence test fluid, preparation method and its application | |
CN103275697B (en) | Di-pyrene amphiphilic fluorescent probe and synthesis method and application thereof | |
Peng et al. | Two cyanoethylene-based fluorescence probes for highly efficient cyanide detection and practical applications in drinking water and living cells | |
CN112724040B (en) | A class of cationic fluorescent probes based on tetraphenylene structure | |
CN111393461B (en) | Palladium ion fluorescent probe compound based on BODIPY and synthetic method thereof | |
CN114276356B (en) | A mitochondria-targeted fluorescent probe and its synthesis method and application | |
CN107235985A (en) | A kind of fluorescence probe for detecting bivalent cupric ion and preparation method and application | |
CN115261015B (en) | A dual-channel fluorescent probe for detecting N2H4 and Cu2+ based on ICT principle and its preparation method and application | |
CN106565752B (en) | A kind of synthesis of fluorescent chemicals and its application in nickel ion detection | |
CN112645941B (en) | Oxazole derivative fluorescent probe and preparation method and application thereof | |
CN108863945A (en) | A kind of phenanthro- imidazoles Fe3+Probe and its preparation and application | |
CN103012375A (en) | Pyridyl triazole methyl substituted acridine derivative, preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |